Last reviewed · How we verify
Fentanyl pectin
At a glance
| Generic name | Fentanyl pectin |
|---|---|
| Also known as | Lazanda, Fentanyl |
| Sponsor | Richard C Reznichek, MD |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Fentanyl Pectin Nasal Spray (FNPS) for Exercise-Induced Breakthrough Dyspnea (PHASE2)
- Intranasal Fentanyl for Management of Pain Associated With Cystoscopic Procedures (PHASE1)
- Prospective Longitudinal Observational Study to Evaluate the Clinical Characteristics and Opioids Treatments in Patients With Breakthrough Cancer Pain
- PEctin Rapid Fentanyl Efficacy Clinical Trial For pAin at Swallowing Undergoing radioTherapy (PHASE3)
- Intranasal Transmucosal Fentanyl Pectin for Breakthrough Cancer Pain in Radiation-induced Oropharyngeal Mucositis
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fentanyl pectin CI brief — competitive landscape report
- Fentanyl pectin updates RSS · CI watch RSS
- Richard C Reznichek, MD portfolio CI